Trial Profile
Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Diverticulitis
- Focus Therapeutic Use
- Acronyms ROAD
- Sponsors Alfasigma
- 13 Oct 2021 Status changed from active, no longer recruiting to discontinued as per Sponsor's decision.
- 18 Jun 2021 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 21 Mar 2021 This trial has been completed in France and Netherlands, according to European Clinical Trials Database record.